KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions to authors
- Article processing charge
- e-submission
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
- Serum Visfatin and Fetuin-A Levels and Glycemic Control in Patients with Obese Type 2 Diabetes Mellitus
- Fethiye Oztop Gunduz, Sembol Turkmen Yildirmak, Mustafa Temizel, Yilmaz Faki, Mustafa Cakmak, Mustafa Durmuscan, Funda Sezgin
- Diabetes Metab J. 2011;35(5):523-528. Published online October 31, 2011
- DOI: https://doi.org/10.4093/dmj.2011.35.5.523
- 65,535 View
- 29 Download
- 10 Crossref
-
Abstract
PDF
PubReader Background Visfatin is an adipokine produced by visceral adipose tissue and has insulin-mimicking effects. Fetuin-A is a hepatic secretory protein that binds the insulin receptor and inhibits insulin action both
in vivo andin vitro . The authors of the present study aimed to investigate the levels of serum visfatin and fetuin-A and their correlation with hemoglobin A1c (HbA1c) and urine albumin levels in patients with type 2 diabetes mellitus (T2DM).Methods A total of 40 obese patients with T2DM (11 males and 29 females; age, 54.47±10.83 years and 23 obese nondiabetic controls (8 males and 15 females; age, 53.04±11.33 years) were included in the study. Age, sex, and body mass index were similar in the 2 groups. Serum visfatin and fetuin-A levels were measured by enzyme-linked immunosorbent assay. HbA1c and urine albumin levels were measured by high performance liquid chromatography and nephelometric method, respectively.
Results Serum levels of visfatin in patients with T2DM (4.03±2.44 ng/mL) were similar to the control group (3.65±3.02 ng/mL). Serum fetuin-A levels were significantly lower in patients with T2DM than the controls (298.75±78.86 and 430.73±94.46 µg/mL, respectively). HbA1c levels were significantly higher in the T2DM group compared with controls (7.33±1.32 and 5.44±0.84%, respectively). Correlations between visfatin, fetuin-A and HbA1c levels were not observed.
Conclusion The present study suggests fetuin-A may play a role in the pathogenesis of T2DM.
-
Citations
Citations to this article as recorded by
- Assessment of serum and salivary visfatin levels in newly diagnosed patients of type-II DM
Faith R. Jerusha, Vandana Raghunath
Journal of Oral and Maxillofacial Pathology.2023; 27(4): 663. CrossRef - Evaluation of the serum visfatin eotaxin and fetuin-A levels of patients with type 2 diabetes mellitus
Hacer KAYHAN KAYA, Abdurrahman ŞERMET, Zafer PEKKOLAY, Ezel TAŞDEMİR, Dilek AYGÜN KEŞİM
Anatolian Current Medical Journal.2022; 4(1): 113. CrossRef - The Association Between Three Adipocytokines (Adiponectin, Resistin and Visfatin) And Thyroid Status in Patients With Type 2 Diabetes Mellitus and Autoimmune Thyroiditis
Š. Sotak, Z. Schroner, I. Lazúrová, M. Felšőci, I. Jochmanová, D. Petrášová, I. Bertková, M. Mitníková, B. Nováková, H. Wagnerová, O. Bobelová
Physiological Research.2021; (6): 865. CrossRef - Prediction of gestational diabetes mellitus in the first trimester: comparison of maternal fetuin-A, N-terminal proatrial natriuretic peptide, high-sensitivity C-reactive protein, and fasting glucose levels
Hatice Kansu-Celik, A. Seval Ozgu-Erdinc, Burcu Kisa, Rahime Bedir Findik, Canan Yilmaz, Yasemin Tasci
Archives of Endocrinology and Metabolism.2019;[Epub] CrossRef - The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies
F. Roshanzamir, M. Miraghajani, M. H. Rouhani, M. Mansourian, R. Ghiasvand, S. M. Safavi
Journal of Endocrinological Investigation.2018; 41(1): 33. CrossRef - Fetuin-A level in type 2 diabetic patients: relation to microvascular complications
Nehal H. Al-Said, Fatma M. Taha, Ghada M. Abdel-Aziz, Marwa S. Abdel-Tawab
The Egyptian Journal of Internal Medicine.2018; 30(3): 121. CrossRef - Serum levels of fetuin A are increased in women with gestational diabetes mellitus
Ozlem Turhan Iyidir, Ceyla Konca Degertekin, Banu Aktas Yilmaz, Alev E. Altinova, Fusun B. Toruner, Nuray Bozkurt, Goksun Ayvaz, Mujde Akturk
Archives of Gynecology and Obstetrics.2015; 291(4): 933. CrossRef - Lower Fetuin-A, Retinol Binding Protein 4 and Several Metabolites after Gastric Bypass Compared to Sleeve Gastrectomy in Patients with Type 2 Diabetes
Mia Jüllig, Shelley Yip, Aimin Xu, Greg Smith, Martin Middleditch, Michael Booth, Richard Babor, Grant Beban, Rinki Murphy, Pankaj K. Singh
PLoS ONE.2014; 9(5): e96489. CrossRef - Preventive roles of swimming exercise and pioglitazone treatment on hepatic dysfunction in a rat model of metabolic syndrome
Hussein F. Sakr, Fahaid H. Al-Hashem, Waffaa M. Hassab El-Naby, Mahmoud A. Alkhateeb, Mohamed Samir A. Zaki, Hesham M. El Refaey, Mohamed D. Morsy
Canadian Journal of Physiology and Pharmacology.2014; 92(2): 162. CrossRef - Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population – results from the PolSenior substudy
Magdalena Olszanecka-Glinianowicz, Aleksander Owczarek, Maria Bożentowicz-Wikarek, Aniceta Brzozowska, Małgorzata Mossakowska, Tomasz Zdrojewski, Tomasz Grodzicki, Andrzej Więcek, Jerzy Chudek
Metabolism.2014; 63(11): 1409. CrossRef
- Assessment of serum and salivary visfatin levels in newly diagnosed patients of type-II DM
First
Prev
